|
Match
|
Document |
Document Title |
|
|
US20090312306 |
TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS
A compound of Formula I:
and a method for treating a 5-HT 2C receptor-mediated disorder in a mammal using the same.
|
|
|
US20090306047 |
HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS
Disclosed are compounds of the formula I
or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof,
wherein
W is a bond, —C(═S)—, —S(O)—, —S(O) 2...
|
|
|
US20090298810 |
IL-8 Receptor Antagonists
This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (II-8).
|
|
|
US20090281074 |
DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM
Drug compositions containing a substituted diamine compound represented by formula (1):
Q 1 -Q 2 -r-N(R 1 )-Q 3 -N(R 2 ) ...
|
|
|
US20090275563 |
Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy
Patients suffering from serotonin-mediated diseases or conditions, such as depression, may be treated by administering an effective combined amount of a 5-HT7 receptor antagonist and a serotonin...
|
|
|
US20090270370 |
FUSED HETEROCYCLIC COMPOUNDS
Certain fused pyrrole- and pyrazole-containing heterocyclic compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases.
|
|
|
US20090253654 |
CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT
The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and/or acting...
|
|
|
US20090239844 |
ACE INHIBITOR-VASOPRESSIN ANTAGONIST COMBINATIONS
Combinations of ACE inhibitors and vasopressin antagonists are useful to slow and reverse the process of ventricular dilation, and CHF in mammals.
|
|
|
US20090239843 |
Bridged diazepan orexin receptor antagonists
The present invention is directed to bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric...
|
|
|
US20090227565 |
Biphenyl Vasopressin Agonists
A compound of the formulae (I) or (II):
wherein:
Y is a moiety selected from NR or —(CH 2 ) n ; wherein R is hydrogen or (C 1 -C 6 ) lower alkyl, and n is 1;
represents:
(1) a...
|
|
|
US20090221554 |
METHOD OF TREATING COGNITIVE IMPAIRMENT
Disclosed is an method of treating cognitive impairment, including administering to a subject in need thereof a combination of a therapeutic agent for neurodegenerative disease and a...
|
|
|
US20090215748 |
FXR agonists for treating vitamin D associated diseases
Provided are certain methods of treating at least one condition that can be treated by elevating the vitamin D receptor (VDR) activity level in a patient with at least one farnesoid X receptor...
|
|
|
US20090203577 |
Azepinoindole Derivatives As Pharmaceutical Agents
The present invention relates to compounds of formula I, which exhibit affinity for the farnesoid X receptor.
|
|
|
US20090202478 |
Hepatitis C Virus Inhibitors
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such...
|
|
|
US20090203671 |
METHOD OF TREATING CANCER
Methods of treating cancer in patients comprising administering thereto aurora kinase inhibitors and TRAIL (tumor necrosis factor (TNF)-related apoptosis inducing ligand) inhibitors is disclosed.
|
|
|
US20090197868 |
5ht2c receptor modulator compositions and methods of use
The present invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist. In addition, the invention relates to a composition comprising phentermine and a...
|
|
|
US20090197869 |
AZEPINE INHIBITORS OF JANUS KINASES
The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example,...
|
|
|
US20090181947 |
BICYCLIC ENAMINO(THIO)CARBONYL COMPOUNDS
The present invention relates to novel bicyclic enamino(thio)carbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in...
|
|
|
US20090156580 |
ANTI-FOOT-AND-MOUTH DISEASE VIRUS AGENT FOR ANIMAL BELONGING TO FAMILY SUIDAE OR SHEEP, AND METHOD FOR PREVENTION OR TREATMENT OF FOOT-AND-MOUTH DISEASE IN ANIMAL BELONGING TO FAMILY SUIDAE OR SHEEP
Disclosed is an anti-foot-and-mouth disease virus agent for an animal belonging to the Family Suidae, which comprises 3-oxo-3,4-dihyro-2-pyrazincarboxamide or a salt thereof. The agent is extremely...
|
|
|
US20090156639 |
COMPOSITIONS AND METHODS OF TREATMENT USING L-TYPE CALCIUM CHANNEL BLOCKERS AND CHOLINESTERASE INHIBITORS
The present invention relates to composition comprising at least one L-type calcium channel blocker, particularly the compound (+)-isopropyl 2-methoxyethyl...
|
|
|
US20090149446 |
Compositions Comprising Nicotinic Agonists and Methods of Using Same
The disclosure is directed at least in part to compositions and methods comprising nicotinic agonists for treating e.g., nervous system disorders, in particular, to combination therapies that...
|
|
|
US20090137557 |
Calcilytic Compounds
Novel calcilytic compounds, pharmaceutical compositions, methods of synthesis and methods of using them are provided.
|
|
|
US20090136570 |
Taste-Masked Tablets and Granules
Orally administered, taste-masked tablets and granules contain (a) a hydroxypyrimidinone carboxamide, a hydroxy-tetrahydropyridopyrimidinone carboxamide, or a related carboxamide compound, or a...
|
|
|
US20090137554 |
1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
Disclosed are chemical entities including compounds of Formula I
and pharmaceutically acceptable salts thereof, wherein X is chosen from CN, CF 3 , CF 2 H, S(O) n R 8 , and S(O) 2 N(R 9 )R 10 ;...
|
|
|
US20090131407 |
TETRACYCLIC KINASE INHIBITORS
The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula (I): I wherein X, Y, Z, R...
|
|
|
US20090131409 |
1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
Disclosed are chemical entities including compounds of Formula I
and pharmaceutically acceptable salts thereof, wherein X is chosen from CN, CF 3 , CF 2 H, S(O) n R 6 , and S(O) 2 N(R 9 )R 10 ;...
|
|
|
US20090087488 |
GALANTAMINE-CONTAINING CONTROLLED RELEASE ORAL DOSAGE FORMS, PROCESSES FOR THE PREPARATION THEREOF AND USE OF THE MANUFACTURE OF A MEDICAMENT
The present invention relates to controlled release oral dosage forms of galantamine or acceptable salts thereof and processes for the preparation thereof.
|
|
|
US20090088418 |
4-SUBSTITUTED QUINUCLIDINE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF
The present invention relates to compounds and formulations capable of affecting nicotinic acetylcholine receptors (nAChRs), for example, as modulators of specific nicotinic receptor subtypes...
|
|
|
US20090081314 |
Glycemic Control, Diabetes Treatment, and Other Treatments with Acetyl Cholinesterase Inhibitors
There is disclosed a method for glycemic control of a patient having a disease selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance,...
|
|
|
US20090081318 |
TREATMENT OF NEUROADS USING INHIBITORS OF GLYCOGEN SYNTHASE KINASE (GSK)-3
Provided is a method of treating or preventing neurological disease in a subject in need of such treatment or prevention, comprising administering to the subject a therapeutically effective dose of...
|
|
|
US20090069277 |
Compounds and compositions for treating infection
Compounds from 14 Kenyan plants, including from the root of Dovyalis abyssinica and Clutia robusta have been characterized and isolated, and their uses are disclosed.
|
|
|
US20090069295 |
DEUTERIUM-ENRICHED CONIVAPTAN
The present application describes deuterium-enriched conivaptan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
|
|
|
US20090062258 |
FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF
The present invention provides a compound represented by the formula (I) and a salt thereof
wherein: ring A is a 5-membered aromatic heterocycle optionally having substituent(s); R 1 is a...
|
|
|
US20090048234 |
Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
The present invention provides compositions and methods for preventing, treating or reversing neuronal dysfunction in a mammal resulting from exposure to organophosphate nerve agents,...
|
|
|
US20090042862 |
NOVEL COMPOUNDS
The present invention relates to novel bicyclic benzamide derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the...
|
|
|
US20090029965 |
Vasopressin V1a Antagonists
The present invention concerns compounds inter alia according to general formula 1 a . Compounds according to the invention are vasopressin V 1a receptor antagonists. Pharmaceutical compositions...
|
|
|
US20090023706 |
Method of Treating Organophosphorous Poisoning
The present invention is directed to various methods for treating organophosphorus poisoning in an animal that is at risk of exposure to an organophosphorus compound or preventing organophosphorus...
|
|
|
US20090017015 |
Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
The invention relates to the use of a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof for the prevention, delay of progression or the treatment of...
|
|
|
US20080318929 |
Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta
Disclosed are novel compounds of formula (I) wherein R 1 , R 2 , R 3 , and R 4 and A are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety...
|
|
|
US20080293680 |
Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II
The invention relates to a compound of the formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are defined as in the specification and claims and to its use for treating or...
|
|
|
US20080293693 |
Treatment or Prevention of Ovarian Hyperstimulation Syndrome (Ohss) Using a Dopamine Agonist
Disclosed herein is a method for preventing ovarian hyperstimulation syndrome in a subject by administering an effective amount of a dopamine agonist in a pharmaceutically acceptable carrier. Also...
|
|
|
US20080293694 |
New compounds
The present invention relates to novel compounds of formula (I):
wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as described herein, to pharmaceutical compositions comprising the compounds,...
|
|
|
US20080287423 |
Use of Azapaullones For Preventing and Treating Pancreatic Autoimmune Disorders
This invention relates to the use of azapaullones, particularly in combination with immunomodulating agents, in the prevention, and/or treatment of pancreatic autoimmune disorders, e.g. type I...
|
|
|
US20080279846 |
METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS
The present invention provides compostions and methods useful for treating and preventing neurodegenerative disease and neurologically related disorders by inhibition of Lp-PLA2. The compositions...
|
|
|
US20080269195 |
Compounds Having Affinity For the Dopamine D3 Receptor and Uses Thereof in Medicine
Compounds of formula (I) or a salt thereof are disclosed:
wherein, A, m R 1 , R 2 , R 3 , q, W 1 , W 2 , R 4 and R 5 are as defined in the description. Processes for preparation and uses of...
|
|
|
US20080261953 |
Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
Compounds and compositions are provided for treatment or amelioration of one or more symptoms of α-synuclein toxicity, α-synuclein mediated diseases or diseases in which α-synuclein fibrils are...
|
|
|
US20080261954 |
Cholinergic Enhancers with Improved Blood-Brain Barrier permeability for the Treatment of Diseases Accompanied by Cognitive Impairment
The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and/or acting...
|
|
|
US20080254131 |
CONTROLLED-RELEASE GALANTAMINE FORMULATIONS
Controlled-release galantamine formulations, including controlled-release particles, pellets, granules, and spheres are described. Controlled-release particles, pellets, granules, and spheres with...
|
|
|
US20080242658 |
Inhibitors of Iap
Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula I
|
|
|
US20080221084 |
METHOD FOR REDUCING INFARCTION USING VASOPRESSIN ANTAGONIST COMPOUNDS, AND COMPOSITIONS AND COMBINATIONS THEREFOR
The present invention relates to a method for reducing infarction comprising administering to a patient ion need thereof a therapeutically effective amount of a composition comprising as an active...
|